Edition:
United Kingdom

Medivir AB (MVIRb.ST)

MVIRb.ST on Stockholm Stock Exchange

40.70SEK
23 May 2018
Change (% chg)

-0.75kr (-1.81%)
Prev Close
41.45kr
Open
41.05kr
Day's High
41.35kr
Day's Low
40.35kr
Volume
10,045
Avg. Vol
96,199
52-wk High
84.25kr
52-wk Low
34.10kr

Chart for

About

Medivir AB is a Sweden-based pharmaceutical company engaged in the research, development and sale of drugs against widespread diseases, with protease and polymerase as its target enzymes. The Company’s research focuses on developing small molecule pharmaceuticals, primarily against infectious diseases caused by viruses. The... (more)

Overall

Beta: 1.15
Market Cap(Mil.): kr1,394.06
Shares Outstanding(Mil.): 19.84
Dividend: --
Yield (%): --

Financials

  MVIRb.ST Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -14.03 -- --
ROI: -33.02 1.57 14.38
ROE: -34.12 2.43 16.07

BRIEF-Medivir Q1 operating loss narrows

* MEDIVIR Q1 NET TURNOVER TOTALED SEK 4.5 MILLION (17.8 M)OF WHICH SEK 4.5 MILLION (13.7 M) COMPRISED THE FIRST QUARTER’S ROYALTIES

27 Apr 2018

BRIEF-Medivir completes directed issue of around 155 mln SEK

* MEDIVIR HAS COMPLETED A DIRECTED SHARE ISSUE OF APPROXIMATELY 155 MSEK

02 Feb 2018

BRIEF-Medivir Intends To Make A Directed Share Issue

* MEDIVIR - ‍MEDIVIR IS IN DISCUSSIONS WITH FDA ON DESIGN OF PIVOTAL PHASE III CTCL STUDY FOR REMETINOSTAT​

01 Feb 2018

BRIEF-Medivir: successful completion of pre-clinical safety studies with MIV-818

* SUCCESSFUL COMPLETION OF PRE-CLINICAL SAFETY STUDIES WITH MIV-818, ENABLING START OF PHASE I CLINICAL STUDIES IN 2018 Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

08 Jan 2018

Earnings vs. Estimates